North America Inflammatory Bowel Disease Treatment Market Size & Outlook
Related Markets
North America inflammatory bowel disease treatment market highlights
- The North America inflammatory bowel disease treatment market generated a revenue of USD 11,942.4 million in 2023.
- The market is expected to grow at a CAGR of 3.2% from 2024 to 2030.
- In terms of segment, crohn's disease was the largest revenue generating type in 2023.
- Ulcerative Colitis is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, Canada is expected to register the highest CAGR from 2024 to 2030.
North America data book summary
Market revenue in 2023 | USD 11,942.4 million |
Market revenue in 2030 | USD 14,933.7 million |
Growth rate | 3.2% (CAGR from 2023 to 2030) |
Largest segment | Crohn's disease |
Fastest growing segment | Ulcerative Colitis |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Crohn's Disease, Ulcerative Colitis |
Key market players worldwide | AbbVie Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Biogen Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Merck & Co Inc, Johnson & Johnson, Celltrion Healthcare |
Other key industry trends
- In terms of revenue, North America region accounted for 57.6% of the global inflammatory bowel disease treatment market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 5,284.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Inflammatory Bowel Disease Treatment Market Scope
Inflammatory Bowel Disease Treatment Market Companies
Name | Profile | # Employees | HQ | Website |
---|---|---|---|---|
Celltrion Healthcare | View profile | 51-100 | Incheon, Inch'on-jikhalsi, South Korea, Asia | http://www.celltrionhealthcare.com/ |
Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
Biogen Inc | View profile | 7570 | 225 Binney Street, Cambridge, MA, United States, 02142 | https://www.biogen.com |
Eli Lilly and Co | View profile | 43000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | https://www.lilly.com |
Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
UCB SA | View profile | 9083 | Allee de la Recherche, 60, Brussels, Belgium, B-1070 | https://www.ucb.com |
Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
North America inflammatory bowel disease treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inflammatory bowel disease treatment market will help companies and investors design strategic landscapes.
Crohn's disease was the largest segment with a revenue share of 62.2% in 2023. Horizon Databook has segmented the North America inflammatory bowel disease treatment market based on crohn's disease, ulcerative colitis covering the revenue growth of each sub-segment from 2018 to 2030.
North America dominated the market in 2022 due to presence of key players in the market, initiatives undertaken by regulatory bodies for funding R&D, increased awareness about the disease, and emerging use of novel treatments & biosimilars.
This can significantly improve availability of therapeutics. Furthermore, increase in manufacturing capacities to expand supply of new drugs is expected to fuel market growth. For instance, in June 2020, Takeda Pharmaceutical Company Ltd. received FDA approval to manufacture Entyvio (vedolizumab) in its manufacturing facility at Brooklyn Park, Minnesota.
Presence of a robust pipeline of drugs and increase in the number of clinical trials of drug candidates in the region are among the major factors expected to boost market growth in North America. Moreover, increase in prevalence of IBD in the region is anticipated to boost market growth.
Reasons to subscribe to North America inflammatory bowel disease treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America inflammatory bowel disease treatment market databook
-
Our clientele includes a mix of inflammatory bowel disease treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America inflammatory bowel disease treatment market , including forecasts for subscribers. This continent databook contains high-level insights into North America inflammatory bowel disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America inflammatory bowel disease treatment market size, by country, 2018-2030 (US$M)
North America Inflammatory Bowel Disease Treatment Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more